» Articles » PMID: 35608806

Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors

Overview
Journal Endocr Pathol
Specialties Endocrinology
Pathology
Date 2022 May 24
PMID 35608806
Authors
Affiliations
Soon will be listed here.
Abstract

Extra-pulmonary neuroendocrine carcinomas (EPNEC) represent a group of rare and heterogenous neoplasms with adverse clinical outcome. Their molecular profile is largely unexplored. Our aim was to investigate if the major transcriptional drivers recently described in high-grade pulmonary neuroendocrine carcinomas characterize distinct molecular and clinical subgroups of EPNEC. Gene expression of ASCL1, NEUROD1, DLL3, NOTCH1, INSM1, MYCL1, POU2F3, and YAP1 was investigated in a series of 54 EPNEC (including 10 cases with mixed components analyzed separately) and in a group of 48 pulmonary large cell neuroendocrine carcinomas (P-LCNEC). Unsupervised hierarchical cluster analysis classified the whole series into four major clusters. P-LCNEC were classified into two major clusters, the first ASCL1/DLL3/INSM1-high and the second (including four EPNEC) ASCL1/DLL3-low but INSM1-high. The remaining EPNEC cases were sub-classified into two other clusters. The first showed INSM1-high and alternative ASCL1/DLL3 or NEUROD1 high expression. The second was characterized mainly by MYCL1 and YAP1 overexpression. In the ten cases with mixed histology, ASCL1, DLL3, INSM1, and NEUROD1 genes were significantly upregulated in the neuroendocrine component. Higher gene-expression levels of NOTCH1 and INSM1 were associated with lower pT stage and negative nodal status. Low INSM1 gene expression was associated with shorter overall survival in the entire case series (p = 0.0017) and with a trend towards significance in EPNEC, only (p = 0.06). In conclusion, our results show that EPNEC possess distinct neuroendocrine-lineage-specific transcriptional profiles; moreover, low INSM1 gene expression represents a novel potential unfavorable prognostic marker in high-grade NECs including those in extra-pulmonary location.

Citing Articles

Molecular subtypes and prognostic factors of lung large cell neuroendocrine carcinoma.

Liu T, Chen X, Mo S, Zhou T, Ma W, Chen G Transl Lung Cancer Res. 2024; 13(9):2222-2235.

PMID: 39430332 PMC: 11484736. DOI: 10.21037/tlcr-24-292.


Activating Invasion and Metastasis in Small Cell Lung Cancer: Role of the Tumour Immune Microenvironment and Mechanisms of Vasculogenesis, Epithelial-Mesenchymal Transition, Cell Migration, and Organ Tropism.

He C Cancer Rep (Hoboken). 2024; 7(10):e70018.

PMID: 39376011 PMC: 11458887. DOI: 10.1002/cnr2.70018.


Prognostic significance of tertiary lymphoid structures in gastric neuroendocrine carcinoma with association to delta-like ligand 3 and neuroendocrine expressions.

Ahn B, Kim D, Kim M, Jeong S, Song I, Kim J Gastric Cancer. 2024; 28(1):27-40.

PMID: 39352632 DOI: 10.1007/s10120-024-01557-8.


Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?.

Uccella S Endocr Pathol. 2024; 35(2):91-106.

PMID: 38470548 PMC: 11176254. DOI: 10.1007/s12022-024-09807-2.


Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.

Ooki A, Osumi H, Fukuda K, Yamaguchi K Cancer Metastasis Rev. 2023; 42(3):1021-1054.

PMID: 37422534 PMC: 10584733. DOI: 10.1007/s10555-023-10121-2.


References
1.
Roy M, Buehler D, Zhang R, Schwalbe M, Baus R, Salamat M . Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites. Endocr Pathol. 2018; 30(1):35-42. DOI: 10.1007/s12022-018-9559-y. View

2.
Simbolo M, Mafficini A, Sikora K, Fassan M, Barbi S, Corbo V . Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol. 2016; 241(4):488-500. PMC: 5324596. DOI: 10.1002/path.4853. View

3.
Hermans B, Derks J, Thunnissen E, van Suylen R, den Bakker M, Groen H . DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. Lung Cancer. 2019; 138:102-108. DOI: 10.1016/j.lungcan.2019.10.010. View

4.
Borromeo M, Savage T, Kollipara R, He M, Augustyn A, Osborne J . ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell Rep. 2016; 16(5):1259-1272. PMC: 4972690. DOI: 10.1016/j.celrep.2016.06.081. View

5.
Jesinghaus M, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M . Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Mod Pathol. 2017; 30(4):610-619. DOI: 10.1038/modpathol.2016.220. View